Acrux Limited, together with its subsidiaries, develops and commercializes specialty and generic topical pharmaceuticals in Australia, Switzerland, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. The company was founded in 1998 and is based in West Melbourne, Australia.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+61-3-83790100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.29 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Acrux (ASX:ACR) Frequently Asked Questions
What is Acrux's stock symbol?
Acrux trades on the ASX under the ticker symbol "ACR."
Has Acrux been receiving favorable news coverage?
News headlines about ACR stock have trended somewhat positive on Wednesday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Acrux earned a news impact score of 0.9 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Acrux.
Who are some of Acrux's key competitors?
Some companies that are related to Acrux include Ampliphi Biosciences (APHB), BioTime (BTX), MediGene (MDG1), CorMedix (CRMD), IMV (IMV), Emerald Health Therapeutics (EMH), Verseon (VSN), Cynata Therapeutics (CYP), Fennec Pharmaceuticals (FRX), Antibe Therapeutics (ATE), Burcon NutraScience (BU), Matinas BioPharma (MTNB), Sirona Biochem (SBM), Medlab Clinical (MDC) and Immutep (IMM).
What other stocks do shareholders of Acrux own?
Who are Acrux's key executives?
Acrux's management team includes the folowing people:
- Mr. Michael Kotsanis B.Sc., BSc, GradDipBus, MBus, CEO, MD & Exec. Director (Age 53)
- Mr. Tim Bateman, CFO & Company Sec.
- Ms. Felicia Colagrande BSc (Hons), MBA, Product Devel. & Technical Affairs Director
- Mr. Charles O'Sullivan B. Pharm, Grad. Dip. Epi. & Biostats, Portfolio Director
What is Acrux's stock price today?
One share of ACR stock can currently be purchased for approximately A$0.23.
How big of a company is Acrux?
What is Acrux's official website?
How can I contact Acrux?
Acrux's mailing address is 103-113 Stanley St, MELBOURNE, VIC 3003, Australia. The company can be reached via phone at +61-3-83790100.
MarketBeat Community Rating for Acrux (ASX ACR)
MarketBeat's community ratings are surveys of what our community members think about Acrux and other stocks. Vote "Outperform" if you believe ACR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACR will underperform the S&P 500 over the long term. You may vote once every thirty days.
